Fig. 5: Macrophages are essential for the antitumor effects of pladienolide B.
a Schematic diagram of tumor transplantation and drug administration in mice. ID8 cells (2 × 105/mouse) were subcutaneously injected into the left groin of C56BL/6 mice (6–8 weeks old). After three days, mice were randomized into treatment cohorts accordingly (n = 6 for each group) and given drug treatment: vehicle (10% DMSO in PBS) or pladienolide B (0.5 mg/kg, every 3 days, 6 times) or clodronate liposomes (150 µL/mouse, every 2 weeks) or pladienolide B + clodronate liposomes. After the tumors were palpable, tumor volume was evaluated every 3 days. Pladienolide B treatment was stopped at day 18 and clodronate liposomes exposure was continued. Then tumor growth was kept to be observed for another 2 weeks. Clodronate liposomes were used to clear macrophage. b Growth curve of tumor volume. c Image of transplantation tumors. d The proportion of CD8+ cells to CD3+ cells and the proportion of IFN-γ + CD8+ cells to CD8+ cells. p values were determined by One-Way ANOVA tests. *p < 0.05. **p < 0.01. ***p < 0.001.
